Introduction

Clonidine is a centrally acting alpha-2 adrenergic agonist used in hypertension.

Because abrupt discontinuation can cause rebound hypertension, we plan supply on this molecule against committed forecasts and buffer stock rather than reactive ordering a stockout here has clinical consequences, not merely commercial ones.

Complete CTD, ACTD and eCTD dossiers, bioequivalence data, CoPP, FSC and ICH Zone IVb stability are supplied for MOH registration.

Product Overview

Field	Details
Product Name	Clonidine Tablets
INN / Generic Name	Clonidine hydrochloride
Therapeutic Class	Centrally acting alpha-2 adrenergic agonist antihypertensive
Mechanism (brief)	Stimulates presynaptic alpha-2 receptors in the brainstem, suppressing sympathetic outflow and reducing peripheral vascular resistance
Indication	Hypertension, per approved local labelling
API Quality	Manufactured using DMF-grade Clonidine Hydrochloride
Pharmacopoeial Standard	USP Clonidine Hydrochloride Tablets USP; BP available [CONFIRM per SKU]
Available Strengths	0.1 mg, 0.2 mg and 0.3 mg tablets
CRITICAL WARNING	Do not discontinue abruptly. Sudden cessation can cause rebound hypertension, with rapid blood pressure rise beginning 8 to 24 hours after the last dose.
Discontinuation	Taper gradually over 2 to 4 days minimum. Patients on therapy longer than four weeks may require slower reduction.
Beta-Blocker Sequencing	Where a beta-blocker is co-prescribed, it should be withdrawn first, several days before beginning the clonidine taper
Substitution Warning	Immediate-release and extended-release clonidine products must NOT be substituted on a milligram-per-milligram basis, because pharmacokinetic profiles differ
Governing Quality Attribute	Content uniformity at 0.1 mg this is a genuinely low-dose product
Solubility Position	Clonidine hydrochloride is freely water-soluble and the dose is very low, which supports a strong BCS-based biowaiver argument [CONFIRM formal classification]
Shelf Life	36 Months [CONFIRM against stability data]
Storage	Store at 20–25°C, protect from light and moisture [CONFIRM against your stability data]
Manufacturing Facility	WHO-GMP certified general oral solid dosage block, segregated from beta-lactam operations
Dossier Available	Yes, CTD / ACTD / eCTD format

Strengths, Presentation & Specification

Clonidine Tablets 0.1 mg

The foundation strength and the one that does the most work.

It serves as the usual starting dose, as the increment for upward titration, and most importantly as the step that makes a controlled taper possible.

Because clonidine must be withdrawn gradually, a range without the 0.1 mg strength leaves prescribers unable to taper safely.

At 0.1 mg this is also a genuinely low-dose tablet, making content uniformity the governing quality risk.

Target buyers include cardiology and general medicine distributors, hospital and retail chains, MOH tender procurement.

Clonidine Tablets 0.2 mg

The common maintenance strength for established patients, reducing tablet burden.

Typically tendered alongside the 0.1 mg strength rather than separately, since a patient on 0.2 mg who needs to stop will require 0.1 mg tablets to taper safely.

Clonidine Tablets 0.3 mg

The higher maintenance strength, used in patients requiring larger daily doses.

Withdrawal reactions have been associated particularly with previous administration of high oral doses, so patients on this strength are the group for whom taper availability matters most another reason to stock the full range.

Specification & Testing

Regulatory & Dossier Support

Dossier Availability

CTD (Common Technical Document) ICH-aligned for regulated markets; ACTD for Philippines, Vietnam, Myanmar, Indonesia, Cambodia; eCTD for authorities requiring electronic submission.

Module 3 quality documentation includes blend and content uniformity data, process validation, dissolution method validation and photostability.

Stability data includes real-time and accelerated under ICH Zone IVb (30°C / 75% RH).

Module 1 labelling carries the discontinuation warning, taper instruction and non-substitution statement in full.

Bioequivalence & Biowaiver Position

Clonidine hydrochloride is freely soluble in water and the therapeutic dose is very small, so absorption is not solubility-limited.

That makes a BCS-based biowaiver a realistic and often straightforward route for immediate-release tablets where authorities accept it.

Where a biowaiver is pursued, the argument rests on demonstrated high solubility across the physiological pH range plus rapid and comparable dissolution for both test and reference product.

In-vivo BE study data is available; strength-to-strength biowaiver may be accepted across 0.1 mg, 0.2 mg and 0.3 mg where proportional similarity and comparable dissolution profiles are demonstrated.

NOTE: This biowaiver discussion applies to immediate-release tablets only.

Extended-release clonidine has a different pharmacokinetic profile and must not be substituted on a milligram-per-milligram basis.

Drug Master File (DMF)

Drug Master File reference for Clonidine Hydrochloride API is available for cross-referencing in your registration dossier.

API is sourced against a qualified vendor with impurity, residual solvent, elemental impurity and particle size characterisation.

Particle size matters for blend uniformity at this dose.

CDSCO / Indian DMF reference is accepted by large number of importing authorities.

Manufacturing Compliance

WHO-GMP certified manufacturing facility, audit-ready, with inspection reports shared on NDA basis.

Site Master File (SMF) is available for regulatory submissions.

Clonidine is not a beta-lactam or cytotoxic and is not subject to international drug control conventions.

Production runs in general oral solid dosage block physically segregated from beta-lactam operations, with validated cleaning between products.

Low-dose blending controls are the substantive manufacturing question.

At 0.1 mg per tablet, blend homogeneity, API particle size and segregation control during compression govern content uniformity, and we document these as controlled process parameters rather than as release testing outcomes.

Compliant with NAFDAC (Nigeria), PPB (Kenya), FDA Philippines, DRAP (Pakistan) and INVIMA (Colombia).

Complete Documentation Package (Per Shipment)

Document	Purpose
Certificate of Analysis (CoA)	Confirms batch quality against the agreed specification
Certificate of Pharmaceutical Product (CoPP / CPP)	Required for MOH registration in most importing countries
Free Sale Certificate (FSC)	Confirms the product is freely sold in the country of manufacture
Method of Analysis (MOA)	Analytical methodology mandatory dossier component
GMP Certificate	Confirms manufacturing site compliance
Stability Data	Real-time and accelerated ICH Zone IVb, plus photostability
BE Study Report or Biowaiver Justification	States explicitly which route was taken and on which strength
Content Uniformity Data	Batch-level the governing quality attribute at 0.1 mg
Blend Uniformity Data	Through granulation and compression, not only at release
Dissolution Profile Report	Across the physiological pH range
Supply Continuity Undertaking	Forecast-based scheduling and buffer stock agreement see Section 5F
Excipient Declarations	For all inactive ingredients

Why Continuity of Supply Is a Safety Control on This Molecule

On almost every other product in this portfolio, a stockout means a patient switches brand or waits.

On clonidine, an interrupted supply is pharmacologically identical to abrupt discontinuation and abrupt discontinuation is the recognised mechanism of rebound hypertension.

Blood pressure may begin rising 8 to 24 hours after the last dose.

Missing even a few doses can precipitate it.

That means buffer stock on this molecule is not inventory prudence; it is the control that prevents the harm.

Sudden withdrawal of immediate-release clonidine has produced nervousness, agitation, headache and tremor, accompanied or followed by a rapid rise in blood pressure and elevated plasma catecholamine concentrations.

In rare instances, hypertensive encephalopathy, cerebrovascular accidents and death have been reported.

The reaction is more pronounced after cessation of long-term therapy and has been associated particularly with previous high oral doses and with continued beta-blocker therapy.

Clinical Indications & Therapeutic Information

Clonidine is a centrally acting alpha-2 adrenergic agonist.

It stimulates presynaptic alpha-2 receptors in the brainstem, suppressing sympathetic outflow from the central nervous system and reducing peripheral vascular resistance, heart rate and blood pressure.

Approved indication: hypertension, per approved local labelling. Where a market’s registration covers additional indications, local labelling governs.

Discontinuation warning: sudden cessation of immediate-release clonidine has resulted in nervousness, agitation, headache and tremor, accompanied or followed by a rapid rise in blood pressure.

Rare reports include hypertensive encephalopathy, cerebrovascular accidents and death.

Dose should be reduced gradually over 2 to 4 days minimum, with slower reduction for patients treated longer than four weeks.

Beta-blocker interaction on withdrawal: where a beta-blocker is co-administered, the rebound reaction is amplified, and the beta-blocker should be withdrawn first, several days before beginning the clonidine taper.

Non-substitution: immediate-release and extended-release clonidine products have differing pharmacokinetic profiles and must not be substituted on a milligram-per-milligram basis.

This must be explicit in local labelling wherever both presentations are available.

Hypotension, bradycardia and syncope are recognised effects; titration should be gradual and vital signs monitored in patients at risk.

Target Export Markets

Africa: Nigeria, Kenya, Ghana, Egypt, Tanzania, Uganda, Ethiopia, Zambia, Côte d’Ivoire. Registration support through NAFDAC, PPB, FDA Ghana, TFDA. Hypertension prevalence is among the largest chronic disease burdens in the region. English and French labelling available.

Southeast Asia: Philippines, Vietnam, Myanmar, Cambodia, Indonesia, Bangladesh, Thailand. ACTD dossier format supplied as standard. ICH Zone IVb stability data is prerequisite.

Latin America: Colombia, Peru, Ecuador, Bolivia, Guatemala, Dominican Republic. USP pharmacopoeial standard preferred. Spanish and Portuguese labelling available. CTD format with local regulatory adaptation.

Middle East & CIS: Iraq, Jordan, Yemen, Uzbekistan, Kazakhstan, Azerbaijan. GMP Certificate and CoPP are primary registration requirements. Arabic and Russian labelling available.

Export Packaging & Supply Chain

Primary Packaging Options

Presentation	Packaging Options
Clonidine Tablets 0.1 mg	Alu-Alu blister 10×10 and 3×10; HDPE bottle of 30 / 100 with induction seal and child-resistant closure
Clonidine Tablets 0.2 mg	Alu-Alu blister 10×10 and 3×10; HDPE bottle of 30 / 100
Clonidine Tablets 0.3 mg	Alu-Alu blister 10×10; HDPE bottle of 30
Chronic-therapy packs	28-day or calendar blister presentations, which support adherence and make a missed dose visible [TBC]

Calendar or 28-day blister formats carry real weight on this molecule, because a patient who cannot see that they have missed doses is at risk of unintended partial withdrawal.

Clonidine is pharmacologically potent at very low doses and the tablets are small; where bottle presentations are supplied, child-resistant closures should be specified rather than treated as optional.

Labelling & Customisation

Private label manufacturing available with your brand name and artwork, subject to unchanged regulatory content.

Multi-lingual labelling available in English, French, Spanish, Portuguese, Arabic, Russian.

Mandatory artwork content: the do-not-stop-suddenly instruction in plain language, the taper direction, the beta-blocker sequencing note, the non-substitution statement where an extended-release product exists in the market, storage statement and country-specific registration fields.

Private label flexibility does not extend to safety labelling.

The specific non-negotiable is the discontinuation warning on the carton face.

Patients stop antihypertensives on their own judgement far more often than prescribers do, and a warning buried in a folded leaflet does not reach the person making that decision.

Logistics & Supply

Incoterms: FOB, CIF, CFR, EXW as per buyer requirement.

No cold chain required; protect from light, moisture and sustained heat.

Supply planning is a stated commitment on this product.

We schedule against committed annual forecasts and recommend buffer stock sized to taper duration rather than to reorder lead time.

Why Source Clonidine Tablets From Us?

• Continuity Treated as a Safety Obligation An interrupted supply is pharmacologically identical to abrupt discontinuation. We plan against committed forecasts and recommend buffer stock sized to taper duration.

• Full Strength Range 0.1, 0.2 and 0.3 mg. The 0.1 mg strength makes a controlled taper possible. We encourage buyers to register the full range.

• Low-Dose Uniformity Controlled at Source Blend homogeneity and API particle size govern content uniformity. We document these as controlled process parameters.

• Favourable Biowaiver Position Clonidine hydrochloride is freely water-soluble at a very low dose, supporting a straightforward BCS-based biowaiver argument.

• Discontinuation Warning on the Carton Face Not buried in the leaflet. Patients stop antihypertensives on their own judgement.

• WHO-GMP Certified Manufacturing Segregated general oral solid facility with validated cleaning. GMP certificate and SMF shared on request.

Frequently Asked Questions

Ready to Source Clonidine Tablets FDF?

Share your target market, required strengths and expected annual volume, and our export team will respond with applicable specification, the bioequivalence route that authority requires, dossier format, pack options and a supply schedule that includes buffer stock.

If you are at technical evaluation stage, request the content uniformity and dissolution summaries and a sample CoA.